[Form 4] Kestra Medical Technologies, Ltd. Insider Trading Activity

Rhea-AI Filing Summary

Conor Hanley, a director of Kestra Medical Technologies, Ltd. (KMTS), reported acquisition of 13,120 restricted stock units (RSUs) on 09/04/2025. The filing states each RSU converts to one common share. Following the reported grant, Hanley beneficially owns 13,120 shares attributable to these RSUs. The award vests in two tranches: 2,212 RSUs vest on 06/04/2026 and 10,908 RSUs vest on 09/04/2026, each contingent on continued service through the vesting date. The Form 4 was signed by an attorney-in-fact on 09/08/2025.

Positive

• Alignment with shareholders: RSUs convert to common shares and vest over time, aligning director incentives with long‑term performance
• Clear vesting schedule: Specific vesting dates (06/04/2026 and 09/04/2026) provide transparency on when dilution may occur

Negative

• Potential dilution: 13,120 shares will be issuable upon vesting, which could dilute existing shareholders if settled in shares
• No context on total share count: Filing does not state company’s total outstanding shares, so investor impact cannot be quantified

Insights

Corporate Governance Expert

TL;DR: Director received time‑based RSUs that vest next year, reflecting routine compensation alignment with shareholder interests.

The disclosure shows a standard, time‑based equity grant to a director rather than an open‑market purchase or sale. The two‑tranche vesting schedule over 2026 ties future ownership to continued service and aligns incentives with long‑term shareholder outcomes. No exercise price or cash transaction is reported because these are RSUs representing one share each on settlement. The filing contains no indication of acceleration, change in control terms, or immediate disposition.

Securities Analyst

TL;DR: This Form 4 reports a non‑cash compensation grant; it is informational and unlikely to move valuation materially.

The 13,120 RSU grant increases potential dilution if vested and settled, but the filing provides only the grant and vesting dates, not total outstanding shares or expected settlement timing beyond vesting contingent on service. Without additional metrics like total share count or prior holdings, the materiality to shareholders is limited. The submission was executed by an attorney‑in‑fact and signed on 09/08/2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hanley Conor

(Last) (First) (Middle)

C/O KESTRA MEDICAL TECHNOLOGIES, LTD.

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WA 98033

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/04/2025		A		13,120(1)	A	(1)	13,120	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported securities represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. 2,212 RSUs will vest on June 4, 2026 and 10,908 RSUs will vest on September 4, 2026, in each case subject to the Reporting Person's continued service through such date.

	/s/ Traci S. Umberger as attorney-in-fact for Conor Hanley	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Conor Hanley report on Form 4 for KMTS?

He reported receipt of 13,120 restricted stock units (RSUs) on 09/04/2025, each convertible into one common share.

When do Hanley’s RSUs vest?

2,212 RSUs vest on 06/04/2026 and 10,908 RSUs vest on 09/04/2026, subject to continued service.

Does the Form 4 show any cash transaction or sale by the insider?

No. The filing reports an acquisition of RSUs (non‑cash award); there are no sales or cash proceeds listed.

How many shares will Hanley beneficially own after this transaction?

The filing states 13,120 shares attributable to the reported RSUs are beneficially owned following the grant.

Who signed the Form 4 and when was it filed?

The Form 4 was signed by Traci S. Umberger as attorney‑in‑fact for Conor Hanley on 09/08/2025.